The list is intended to provide ClinVar a level of assurance about the quality of variant classification data submitted by clinical labs.

Launched in the spring, the Oncomine Knowledgebase Reporter genomic analysis software from Thermo Fisher is proving itself in the pathology lab.

The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.

Going forward, the company will focus on its wholly owned subsidiary Medicinal Genomics Corporation, which conducts cannabis genetics research.

The presence of these variants also suggested a role for microglia in the development of late-onset Alzheimer's disease, the researchers said.

The company aims to commercialize a sequencing instrument based on Helicos' technology and has secured orders from a Shanghai-based genomics startup.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.

Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.

That goal is within reach. And in this paper, we’ll show you how. By reading this white paper, you will learn:

· Why quality control is so challenging for NGS labs

· How reference materials may be the key to quality control

· The 9 key characteristics of sufficient NGS reference materials

· How to use QC metrics to monitor the health of your NGS assays

What’s been holding back more widespread adoption of liquid biopsy testing?

Lack of adequate circulating tumor DNA reference materials for developing and measuring safe, accurate and reproducible assays has been a challenge for clinical labs

Liquid biopsies are poised to revolutionize cancer diagnosis and therapy, but until now, advances in diagnostic technology - particularly at the low end of the sample input and sensitivity spectrum - have been hampered by the lack of ability of labs to reproducibly measure and assess the assay’s performance.